Aska Pharmaceutical shareholders approve countermeasures: Nikkei

On June 24, 2026, shareholders of Aska Pharmaceutical Holdings Co., Ltd. approved a conditional activation proposal (Proposal No. 11) aimed at implementing takeover defense measures against a significant shareholder, Dalton Investments and its joint holders. The proposal, formally presented as a shareholder vote, was designed to restrict Dalton's ability to acquire additional shares and to suppress its influence as a shareholder.

Dalton and its joint holders had previously expressed strong opposition to the proposal, arguing that it undermined free share trading and equal treatment of shareholders. They emphasized that their engagement with Aska was intended to enhance corporate value and not to force a going-private transaction. Dalton also criticized selective disclosure and failing to engage in constructive dialogue.

The approval of Proposal No. 11 marks a significant development in the ongoing shareholder dispute. It reflects a strategic move by Aska’s management to protect its corporate governance structure and perceived shareholder interests amid pressure from activist investors. However, the market’s reaction to prior announcements by Aska has been mixed, with some observers suggesting that the measures may not be viewed as beneficial to all shareholders.

Aska’s corporate governance policy emphasizes transparency, shareholder equality, and constructive dialogue. The company’s Board of Directors has previously stated that it aims to balance supervision with business operation to achieve sustainable growth. The recent shareholder vote raises questions about whether the company’s actions align with these stated principles.

Going forward, the outcome of this proposal may influence how other Japanese companies approach shareholder activism and corporate governance reforms. Investors are advised to monitor the situation closely, as the implications could extend beyond Aska to broader market dynamics and regulatory considerations.